Multicare Health System

1. GlaxoSmithKline, LLC. $1,013,201 264 payments
2. Amgen Inc. $232,010 4 payments
3. Merck Sharp & Dohme Corporation $142,868 2 payments
4. Novo Nordisk AS $116,243 275 payments
5. Eisai Inc. $94,393 59 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $63,397 25 payments
7. Grifols Therapeutics LLC $59,507 3 payments
8. H. Lundbeck A S $54,486 19 payments
9. Napo Pharmaceuticals Inc $52,268 17 payments
10. Beckman Coulter, Inc. $46,799 7 payments

1. A Randomized, Double-Blind, Placebo-Controlled, Study Evaluating the E $411,386 17 payments
2. Study name not reported $330,262 141 payments
3. AMG 407 (OTEZLA) - Ph 3 COVID Consortium Study $173,118 1 payment
4. A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. $137,053 1 payment
5. A Phase III, Randomized, Controlled, Observer-Blind Study to Demonstra $134,405 65 payments
6. A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin IVIG Plus Standard Medical Treatment SMT Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the In $59,507 3 payments
7. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome $55,792 46 payments
8. A Phase 3 Multicenter, Randomized, Double Blind Placebo-Controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients with Solid Tumors Receiving Targeted-Cancer Therapies with or without Standar Chemotherapy $52,268 17 payments
9. HF Ref Interval (CHF-04-18) $43,249 3 payments
10. Nn8640-4263 $41,813 107 payments

1. Other $2,750 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.